Drug Database
IN

insulin glargine (Abasaglar / Basaglar / LY2963016)

✓ Approved

Cipla Inc · INSR · 重组蛋白

什么是 insulin glargine?

insulin glargine 是一种重组蛋白,由Cipla Inc研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Subcutaneous Injection。

药物档案

商品名Abasaglar, Basaglar, LY2963016
公司Cipla Inc
药物类别重组蛋白, 多肽类
分子靶点INSR
给药途径Injectable (Others), Subcutaneous Injection
状态Approved

作用机制

分子靶点

insulin glargine 作用于 1 个分子靶点:

INSRinsulin receptor (CD220, HHF5)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

insulin glargine 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Metabolism and nutrition disordersType 1 diabetes mellitus✓ Approved
Metabolism and nutrition disordersType 2 diabetes mellitus✓ Approved

相关研究文献

PubMedOpen life sciences2026-11-20

Massive high-concentration long-acting insulin overdose with suicidal intent - a case report.

Popiołek Alicja A, Bielun Kinga K, Niemczuk Ewa E, Pulkowski Grzegorz G

Intentional insulin overdose has been reported both in individuals with diabetes and in non-diabetic individuals who have access to insulin. As diabetology and insulin therapy continue to evolve, the pharmacodynamic profiles of insulin preparations have also changed, which may influence the clinical course of insulin overdose and poisoning. This case illustrates the prolonged metabolic consequences of a massive overdose of insulin glargine U300 in a non-diabetic individual (a total of 3,150 units administered subcutaneously). Despite its ultra-long-acting formulation, the duration of clinically significant hypoglycemia substantially exceeded that expected based on the pharmacokinetic profile, necessitating continuous intravenous glucose administration for 11 days. Throughout her hospital stay, the patient also required supplementation with phosphate, magnesium, and potassium to correct persistent electrolyte disturbances. This case highlights the importance of prolonged monitoring, aggressive glucose replacement, correction of associated electrolyte abnormalities, and multidisciplinary psychiatric management.

PMID 43061603
阅读全文 →
PubMedmedRxiv : the preprint server for health sciences2026-11-20

Insulin genetic clusters and clinical outcomes in Hispanics/Latinos.

Reynolds Kaylia M KM, Lash James P JP, Morris Andrew P AP, Daviglus Martha M et al.

Increased fasting insulin reflects insulin resistance and is as a precursor to type 2 diabetes and a risk factor for kidney, heart and liver diseases and mortality. Cluster-specific fasting insulin polygenic scores (PS) characterize insulin resistance mechanisms based on insulin-related genetic associations with metabolic traits, and they have not been evaluated for liver outcomes. We calculated seven previously developed FI cluster-specific PS, including non-diabetogenic (Preserved Insulin Secretion, Elevated Insulin Secretion, Proinsulin) and diabetogenic clusters (Adiposity-driven Hyperinsulinemia, Visceral Adiposity, Lipodystrophy, Liver/Lipid) in 12,631 participants of the Hispanic Community Healthy Study/Study of Latinos (HCHS/SOL), and tested their association with type 2 diabetes, cardiovascular, kidney and liver outcomes. We also tested the association of FI clusters with indices of insulin homeostasis in additional 1,316 Hispanic individuals. Among HCHS/SOL participants (mean age 46 years, 59% women, 20% with diabetes), we validated associations of FI cluster-specific PS and the 19 traits used to generate clusters. The Lipodystrophy cluster was associated with type 2 diabetes (p-value =3.5 x 10 -5 ). In addition, the Adiposity-driven Hyperinsulinemia cluster was associated with the hepatic steatosis index (p-value = 2.2 ×10 -17 ) and the fatty liver index (p-value = 1.7 ×10 -14 ), while the Liver/Lipid cluster with liver fibrosis (p-value = 1.5 ×10 -4 ) and lower kidney function (p-value = 5.2 x 10 -5 ). The non-diabetogenic Elevated Insulin Secretion cluster-specific PS was associated with the disposition index (p = 0.0015). These results support insulin resistance mechanisms implicated in type 2 diabetes, liver and kidney outcomes.

PMID 43060701
阅读全文 →
PubMedCommunications biology2026-11-20

Insulin-independent glucose uptake into mouse skeletal muscle by a sodium/glucose linked transporter.

Norman Natalie J NJ, Radzyukevich Tatiana L TL, Chomczynski Peter W PW, Rymaszewski Michal M et al.

Exercise is a cornerstone therapy for diabetes because working skeletal muscles take up glucose at dramatically greater rates than postprandial uptake and, notably, do so without a requirement for insulin. Insulin-independent glucose uptake operates normally during exercise and other conditions when adrenergic stimulation inhibits pancreatic insulin release, and it provides a means of glucose disposal in insulin resistant conditions. However, the mechanisms of insulin-independent glucose uptake are not fully understood. Here, we describe a previously unrecognized glucose uptake pathway in muscle, which we refer to as mSGLT based on shared properties with the sodium/glucose cotransporter family (SGLT/Slc5a). In contrast to the abundant muscle GLUT4 transporter, mSGLT activity is not regulated by insulin, requires Na,K-ATPase-α2 activity, and transports the hexose α-methyl-D-glucoside (αMDG), a glucose derivative that is handled by SGLTs but not GLUT4. mSGLT shares antigenicity with the kidney SGLT2 and localizes to the muscle t-tubules together with Na,K-ATPase-α2 and MAP17, the regulatory subunit of SGLT2. Skeletal muscles do not express a full-length transcript of Slc5a2, and mSGLT shows weak affinity for SGLT2-specific inhibitors. mSGLT may be a muscle SGLT isoform. mSGLT and its regulation offer potential muscle-specific targets for treating hyperglycemia and conditions when insulin-stimulated glucose disposal into muscle is impaired.

PMID 43058179
阅读全文 →
PubMedHealth affairs scholar2026-11-20

Patient-reported affordability of insulin and diabetes supplies three years after Utah's insulin co-pay cap legislation.

Ghule Priyanka P, Schmutz Howard Weston HW, Willis Connor C, Litchman Michelle M et al.

PMID 43061602
阅读全文 →
PubMedBasic & clinical pharmacology & toxicology2026-11-20

Response Heterogeneity to Gegen Qinlian Decoction in Ameliorating Insulin Sensitivity Is Associated With Osteopontin Expression.

Li Dan D, Lao Yujie Y, Qin Yige Y, Li Mengjie M et al.

This study aimed to characterize heterogeneity in the anti-hyperglycaemic response to Gegen Qinlian decoction (GQD) in type 2 diabetes mellitus (T2DM) mice and identify response-associated candidate proteins. T2DM mice were established by a high-fat diet and streptozotocin. Glycaemic control and response heterogeneity were assessed using blood glucose measurements. Serum insulin concentrations and pancreatic histomorphology were used as surrogate markers of pancreatic β-cell function (BCF). Insulin tolerance testing and an insulin-resistant HepG2 cell model were used to assess insulin sensitivity-related phenotypes. Candidate proteins were explored using liver transcriptomic analysis, network pharmacology and literature-informed candidate prioritization, followed by preliminary in vivo and in vitro validation. GQD produced heterogeneous anti-hyperglycaemic responses more closely associated with differences in insulin sensitivity-related measurements than with surrogate BCF indices assessed. Hepatic osteopontin (OPN) expression was elevated in T2DM mice and was selectively downregulated in the exploratory strong-responder subgroup. GQD treatment also reduced elevated OPN expression in insulin-resistant HepG2 cells. Serum OPN concentrations were positively correlated with blood glucose, indicating an association between higher OPN levels and poorer glycaemic outcomes. Wogonin and liquiritigenin were associated with OPN downregulation and increased glucose consumption, with PPARα representing a potential yet unconfirmed mechanistic link. OPN is associated with GQD treatment-response heterogeneity and may represent a candidate response-associated marker.

PMID 43059507
阅读全文 →
PubMedbioRxiv : the preprint server for biology2026-11-20

Ribosome remodeling under glucotoxic conditions impairs β-cell function.

Harvey Abigael Cheruiyot AC, Arriola Jose Santos Navarro JSN, Akintola Olasubomi O, Nguyen Ly L et al.

Diabetes develops when pancreatic β-cells fail to secrete sufficient insulin to meet metabolic demand. Chronic hyperglycemia accelerates β-cell failure and dysregulates mRNA translation before the onset of endoplasmic reticulum stress, but the underlying mechanisms remain unknown. Here, quantitative mass spectrometry of translating ribosomes isolated from β-cells under control and glucotoxic conditions revealed that sustained high glucose remodels ribosome composition by selectively decreasing Ribosomal Protein Lateral Stalk Subunit P1 (RPLP1) on actively translating ribosomes. Knockdown of RPLP1 in MIN6 cells and in primary islets reduced translation of insulin and impaired glucose-stimulated insulin secretion. Depletion of RPLP1 in vivo led to glucose intolerance. Together, our findings indicate that glucotoxicity remodels β-cell ribosomes, leading to selective mRNA translation impairment and decreased insulin secretion. This previously unrecognized mechanism linking metabolic overload to β-cell dysfunction suggests that preserving RPLP1 association with ribosomes could represent a therapeutic strategy for maintaining β-cell function in diabetes. Hyperglycemia dysregulates pancreatic β-cell mRNA-specific translation and impairs glucose-stimulated insulin secretion. Here, Cheruiyot Harvey et al. reveal that sustained high glucose alters the protein stoichiometry of β-cell ribosomes, leading to impaired insulin translation and β-cell function. Sustained high glucose causes RPLP1 dissociation from translating ribosomes of β-cells.Sustained high glucose decreases phosphorylation of RPLP1, which is critical for polysome association.RPLP1-deficient β-cells have impaired insulin mRNA translation, GSIS, and glucose homeostasis.

PMID 43059789
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多insulin glargine